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Background: Hepatitis E virus (HEV) can cause chronic infection with rapid progression to
liver  cirrhosis in immunocompromised patients. HEV seroprevalence in patients with Schis-
tosoma mansoni in Brazil is unknown. We  evaluated the prevalence of past or present HEV
infection in schistosomiasis patients in Recife, Pernambuco, Brazil. A total of 80 patients with
Schistosoma mansoni were consecutively enrolled in a cross-sectional study. Serum samples
were tested for the presence of anti-HEV IgG antibodies by enzyme immunoassay (Wan-
tai  anti-HEV IgG, Beijing, China) and for the presence of HEV RNA using real time reverse
transcriptase-polymerase chain reaction with primers targeting the HEV ORF2 and ORF3.
Clinical and laboratory tests as well as abdominal ultrasound were performed at the same
day  of blood collection.
Results: Anti-HEV IgG was positive in 18.8% (15/80) of patients with SM. None of the samples
tested positive for anti-HEV IgM or HEV-RNA. Patients with anti-HEV IgG positive presented
higher levels of alanine aminotranferase (p = 0.048) and gama-glutamil transferase (p = 0.022)
when  compared to patients without anti-HEV IgG antibodies.
Conclusion: This study demonstrates that the seroprevalence of HEV is high in patients with
Schistosoma mansoni in Northeastern of Brazil. Past HEV infection is associated with higherfrequency of liver enzymes abnormalities. HEV infection and its role on the severity of liver
disease should be further investigated among patients with Schistosoma mansoni.
©  2016 Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND∗ Corresponding author.
E-mail address: marialucia.ferraz@uol.com.br (M.L. Ferraz).
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ntroduction
epatitis E virus (HEV) presents as large epidemics and spo-
adic cases in endemic areas, including genotype 1 in Asia and
frica, genotype 2 in Mexico and Africa, and genotype 4 in
sia. Sporadic cases of genotype 3 occur in Europe, Japan and
he Americas. Genotypes 1 and 2 are restricted to primates and
re transmitted predominantly by the fecal-oral route. Geno-
ypes 3 and 4 infect numerous mammalian species and can
e transmitted through the ingestion of raw or undercooked
eat from infected animals.1
HEV infection usually presents as an acute self-limiting
epatitis, but in immunocompromised patients it can cause
hronic infection with rapid progression to liver cirrhosis.2
razil has been classiﬁed as moderately endemic for HEV, with
eroprevalence ranging from 1% to 4% in the general popula-
ion and 15% in renal transplant recipients.3,4
Schistosoma mansoni (SM) is endemic in up to eight countries
nd islands in Latin America and the Caribbean, including
razil. Up to 6 million people are infected, most of whom live
n Northeastern Brazil and Venezuela, and 25 million are at
isk for the infection.5 Schistosomiasis mansoni may progress
o the most advanced form of disease, which is commonly
bserved in endemic areas. When this hepatosplenic form
ccurs in association with other hepatic disease, such as viral
epatitis, hepatic ﬁbrosis can progress into cirrhosis within a
ew years.6
The seroprevalence of HEV in patients with SM in Brazil is
nknown. The aim of this study was to evaluate the prevalence
f past or present HEV infection in a sample of schistosomiasis
atients in Recife, an endemic region of Northeastern, Brazil,
nd to associate the positivity to HEV infection to clinical and
aboratory abnormalities.
atients  and  methods
tudy  area
ecife is the seventh largest metropolitan area in Brazil with
pproximately 3.9 million inhabitants, the second largest
etropolitan area of the Northern/Northeastern Regions, and
he capital and largest city of the state of Pernambuco.7 In
ddition, the hospital where the study was carried out is
 reference center for patients with the most severe forms
f schistosomiasis mansoni and receives patients from both
ecife metropolitan region as well as from the endemic zone
f Pernambuco State.8
tudy  design
 cross-sectional study was carried out involving patients with
M who  consecutively underwent an ultrasound exam over a
ine-month period at the Division of Gastroenterology, of the
ederal University of Pernambuco, Brazil. The diagnosis of SM
as based on their clinical history of contact with contami-
ated water, positive parasitological stool examination for SM
nd/or reports of prior treatment for this parasite. In addition,6;2 0(3):262–266 263
to be included patients ought to have periportal ﬁbrosis (PPF)
on ultrasound evaluation of the liver.
Male and female patients aged 14 years or older with
SM diagnosis were included. Those with the following crite-
ria were excluded: presence of markers for hepatitis B or
C (anti-HBc and anti-HCV); alcohol intake >210 g/week; and
ultrasound evidence of other liver disease, as expressed by the
presence of steatosis or ﬁne ﬁbrosis diffused throughout the
parenchyma.
During the study period 122 patients were evaluated; how-
ever, 42 patients (32.7%) were excluded due to co-infection
with HBV and/or HCV, alcohol abuse, or other liver diseases
as shown on liver ultrasound. Therefore, 80 patients were
included in this study.
Ultrasound exams were performed by a single operator
(ALCD) using the Siemens Acuson X 150® device with a
3.5 MHz convex transducer for the evaluation of periportal
ﬁbrosis based on the Niamey classiﬁcation, which has six pre-
established patterns of ﬁbrosis (PPF) intensity, ranging from
Pattern A (normal) to Pattern F (very advanced ﬁbrosis).9
According to the pattern of PPF by ultrasound, patients
were divided into three groups: (1) mild group PPF: A + B; (2)
moderate PPF: C + D; and (3) advanced PPF E + F.
Sample  and  data  collection
Serum samples from these patients were collected for lab-
oratory analysis. These included alanine aminotransferase
(ALT), aspartate aminotransferase (AST), alkaline phosphatase
(AP), gamma-glutamyl transpeptidase (GGT), total protein and
albumin, total bilirubin, hemoglobin, leukocyte, and platelet
count.
Normal levels of liver enzymes were ALT ≤ 31 UI/L;
AST ≤ 31 UI/L, AP ≤ 105 UI/L; and GGT ≤ 41 UI/L.
Anti-HEV  antibodies  detection
The presence of anti-HEV IgG antibodies was investigated
through enzyme immunoassay using the WANTAI HEV-IgG
ELISA kit (Beijing Wantai Biological Pharmacy Enterprise,
Beijing, China), strictly according to the manufacturer’s rec-
ommendations. Specimens with positive results were tested
for anti-HEV IgM antibodies using a speciﬁc kit from the same
manufacturer.
RNA  extraction  and  quantitative  RT-PCR
HEV RNA was extracted from fecal samples using QIAamp viral
RNA mini kit (QIAGEN, Hilden, Germany), strictly according to
the manufacturer’s instructions.
Quantitative RT-PCR was performed according to a mod-
iﬁed 1-step triplex real time protocol previously described10
with a set of primers and probe targeting a highly conserved
70 nt long sequence within overlapping parts of ORF2 and
ORF3,11 and another set speciﬁc for a 113 nt sequence of
ORF2.12 A third set of primers and probe targeting the human
RNAseP gene was used as endogenous internal ampliﬁcation
control to certify specimen quality and RNA extraction.13
A plasmid clone from a Brazilian human HEV strain previ-
ously characterized (GenBank accession number KF1528840)14
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Table 1 – Demographic, clinical and laboratory characteristics of schistosomiasis patients according to anti-HEV IgG
status, Northeastern Brazil.
Characteristic Anti-HEV IgG positive Anti-HEV IgG negative p-Value Total
Sex
Male 7 (25.0) 21 (75.0) NS 28  (35.0)
Female 8 (15.4) 44 (84.6) 52 (65.0)
Age 49.2 ± 14.9 50.3 ± 13.4 NS 50.2 ± 13.7
Fibrosis pattern
Mild 1 (50.0) 1 (50.0) NS 2  (2.5)
Moderate 10 (19.2) 42  (80.8) 52  (65.0)
Advanced 4 (15.4) 22 (84.6) 26  (32.5)
Laboratory data
AST 36.1 ± 19.4 30.3 ± 16.4 NS 31.5 ± 17.0
ALT 40.5 ± 28.3 30.6 ± 18.7 0.048a 32.6 ± 21.0
AP 126.7 ± 47.4 116.9 ± 50.6 NS 118.9 ± 49.9
GGT 104.7 ± 65.9 71.0 ± 60.7 0.022a 77.4 ± 62.6
Total bilirubin 1.3 ± 1.1 1.3 ± 0.9 NS 1.3 ± 0.9
Albumin 4.2 ± 0.5 4.3 ± 0.7 NS 4.3 ± 0.6
Total protein 7.6 ± 0.7 7.3 ± 1.0 NS 7.3 ± 1.0
Hemoglobin 12.7 ± 1.7 13.3 ± 1.8 NS 13.2 ± 1.8
Leucocytes 4395 ± 1467 4979 ± 2175 NS 4858 ± 2065
Platelets 136,933 ± 90,066 132,261 ± 84,434 NS 132,263 ± 85,093
Total 15 (18.8) 65  (81.2) 80  (100)
Results are presented as number and percentage for categorical variables and as mean value and standard deviation for continuous vari-
ables. Conventional symbols used: – p > 0.050. Note:  Student’s t-test was used for means comparison of normally distributed variables while
Mann–Whitney U test was used for medians comparison of non-normally distributed variables. Abbreviations:  AST, aspartate aminotransferase;
-glutaALT, alanine aminotransferase; AP, alkaline phosphatase; GGT, gama
a Signiﬁcant at p < 0.050 in Student’s t-test.
was constructed with TOPO® TA cloning® kit (Invitrogen,
Carlsbad, CA, USA) and the primers described. Plasmid
DNA was puriﬁed using QIAprep spin miniprep kit (QIAgen,
Hilden, Germany), linearized and quantiﬁed with the Nan-
odrop ND-1000 instrument (Wilmington, DE, USA) following
transcription to RNA with T7 RNA polymerase (Promega, Madi-
son, WI,  USA). Standard curves were generated using 100 to
1010 copies of plasmid RNA. HEV viral loads were determined
based on the standard curves. While qualitative real time RT-
PCR showed a limit of detection of 5 copies of RNA per reaction,
the linearity of quantitation was set as 50 copies of RNA per
reaction (lowest reproducible viral load). All screening reac-
tions were run in duplicates, with positive results conﬁrmed
in a separate conﬁrmatory reaction.
Statistical  analysis
All data were stored and analyzed using SPSS version 11.0
(SPSS Inc., Chicago, IL, USA). Descriptive statistics consisted of
the characterization of the studied population (demographic,
clinical and laboratory characteristics) and anti-HEV IgG sero-
prevalence through the respective rates or mean/median and
standard deviation (SD) for continuous variables. The univari-
ate analysis consisted of Pearson’s Chi-square test to compare
categorical values. For continuous variables, Student’s t-test
was used to compare means of normally distributed variables,
while non-normally distributed variables were subjected to
Mann–Whitney U test for comparison of medians. Statistical
signiﬁcance level was p < 0.05. All reported values are two-
tailed.myl transpeptidase.
Ethical  aspects
The study protocol was approved by the Institutional Ethics
Committee (162/09 and 86730/14) and all participants signed
an informed consent form.
Results
Study subjects were 14–78 years old, median age 51 years
old (mean ± SD: 50.2 ± 13.7); 52 (65%) patients were female.
Schistosomiasis was clinically classiﬁed as mild (2/80; 2.5%),
moderate (52/80; 65%), or severe (26/80; 32.5%), based on stag-
ing of periportal ﬁbrosis, according to Niamey classiﬁcation.15
Anti-HEV IgG was positive in 15 of the 80 schistosomiasis
patients (18.8%). None of the samples tested positive for anti-
HEV IgM or HEV-RNA. Demographic, clinical and laboratory
data are shown in Table 1.
Patients with anti-HEV IgG antibodies showed signiﬁcant
increase in ALT, and GGT levels, when compared to patients
with no evidence of HEV infection. Other laboratory param-
eters as well as the grade of liver ﬁbrosis determined by
ultrasound analysis showed no differences between the two
groups.
DiscussionThe present data demonstrate that severe cases of SM con-
tinue to take place among outpatients in Northeastern, Brazil.
Close to one-third (32.5%) of the patients exhibited advanced
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atterns (E and F) of periportal ﬁbrosis. These patients with
ore  advanced ﬁbrosis and with low complete blood count
resented with the hepatosplenic form of disease.16 Addi-
ionally, they showed higher levels of portal pressure and
onsequently a greater risk of digestive bleeding, requiring
ollow up in reference centers.9,17
In studies from 1997 to 2006, anti-HEV IgG prevalence var-
ed from 2.0% to 4.3% in blood donors from Southeast and
ortheast Brazil, and from 0% to 2.4% in individuals from
ural and urban areas and in those living in low socioeconomic
ommunities.18 A study on 699 patients of low-socioeconomic
tatus living in Rio de Janeiro in 2002 reported a 2.4%
eroprevalence.19
HEV seroprevalence rates appear to have increased in
ecent years.20 Indeed, in more  recent studies, the prevalence
f HEV infection varied from 5.1% in recyclable waste pickers
rom Central Brazil,21 10% in blood donors from the Southern
art of the country,22 and 12.9% in rural Amazonia.23
In the present study we  found a prevalence of 18.8% of
nti-HEV IgG among a sample of schistosomiasis patients.
uch prevalence is higher than that observed in immuno-
ompetent populations in the country.18–23 There is only
ne study from Brazil that included, among other groups,
atients with SM.  In this study, 10% (3/30) of patients with SM
ere HEV IgG positive, also pointing to a high prevalence of
EV in this speciﬁc group of patients.24 Other studies with
gyptian patients have also demonstrated a higher preva-
ence of HEV infection in schistosomiasis patients.25–27 The
igher prevalence of HEV infection in the schistosomiasis
atients evaluated in the present study could be explained
y the low socioeconomic conditions of these patients, which
ould have favored acquisition of both infections. More-
ver, schistosomiasis may play a role in virus infection
y altering host immune response, favoring the acquisition
f infection. In fact, many  studies demonstrate that the
hronic phase of schistosomiasis infection is characterized
y a state of immune hyporesponsiveness.28 Immunocompro-
ised patients are known to be more  susceptible to hepatitis E
nfection and even to chronic hepatitis E with rapidly progres-
ive cirrhosis, a condition that was not detected in the present
tudy. Fulminant hepatitis and higher mortality are also seen
n individuals with underlying chronic liver disease.1,2 In
eveloped countries, smaller studies have shown a poor prog-
osis for patients with underlying chronic liver disease, but it
s not clear how frequently it occurs, as such patients are not
outinely tested for evidence of HEV infection.1
In the present study, schistosomiasis patients with anti-
EV IgG antibodies showed signiﬁcantly higher levels of ALT
nd GGT, when compared to patients with no evidence of
ast HEV infection. Although schistosomiasis per se can be
ssociated with abnormal liver tests, mainly GGT,29,30 in the
resent study HEV infection seems to have contributed to the
nding of more  elevated levels of the liver enzymes. Accord-
ngly, some studies have reported that anti-HEV IgG positive
atients have higher levels of liver enzymes, when compared
o non-infected patients.31,32 In the study by Hassing et al.,32
IV-infected patients with anti-HEV IgG antibodies showed
igher levels of ALT, when compared to anti-HEV IgG negative
atients, and this elevation was not due to acute or chronic
nfection, since all patients were anti-HEV IgM and HEV-RNA6;2 0(3):262–266 265
negative, like in the present study. The ﬁnding of elevated ALT
and GGT in patients with past HEV-infection, with or without
underlying liver disease, merits further investigation in order
to understand the mechanisms involved in these abnormali-
ties.
In conclusion, this study demonstrates a higher seropreva-
lence of past HEV-infection in patients with SM from Recife,
Northeastern Brazil. Also, schistosomiasis patients with evi-
dence of past HEV-infection have higher levels of ALT and GGT,
suggesting an interaction between these two liver diseases.
Further studies are necessary to evaluate the epidemiology of
HEV infection in SM patients and its impact on the severity of
the disease.
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